Reviva Pharmaceuticals Holdings (RVPH) Price & Analysis

Compare

567 Followers

RVPH Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.30 - $4.28

Previous CloseN/A

Volume1.63M

Average Volume (3M)1.86M

Market Cap

$30.08M

Enterprise Value$8.75M

Total Cash (Recent Filing)$10.36M

Total Debt (Recent Filing)$113.25K

Price to Earnings (P/E)―

Beta1.39

Next Earnings

Nov 17, 2025

EPS Estimate

-0.11

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.12

Shares Outstanding68,003,620

10 Day Avg. Volume928,052

30 Day Avg. Volume1,855,845

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.29

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-0.47

Forecast

1Y Price Target

$5.33

Price Target Upside1111.36% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Drug EfficacyBrilaroxazine demonstrated sustained efficacy across all key symptom domains, underscoring its therapeutic potential in treating schizophrenia.

Partnership OpportunitiesBrilaroxazine is an attractive partnering candidate due to its promising data in treating schizophrenia.

Regulatory PotentialPending favorable FDA feedback, there is potential for an NDA submission for brilaroxazine in schizophrenia, which could represent additional upside.

Bears Say

Capital RequirementsThe company will need to raise additional capital to support its upcoming P3 study, which we factor into our model.

Financial ChallengesThe company, who ended the quarter with $13.5 million in cash, will likely need additional capital in order to move its clinical programs forward.

Price Target ReductionThe analyst has lowered the 12-month price target to $2.00 from $5.00, factoring in dilution and financial challenges.

Reviva Pharmaceuticals Holdings News

Reviva Pharmaceuticals price target lowered to $7 from $14 at Benchmark

Benchmark lowered the firm’s price target on Reviva Pharmaceuticals (RVPH) to $7 from $14 and keeps a Speculative...

19h ago

RVPH

Reviva Pharmaceuticals price target lowered to $2 from $5 at Maxim

Maxim analyst Jason McCarthy lowered the firm’s price target on Reviva Pharmaceuticals (RVPH) to $2 from $5 and...

29d ago

RVPH

Reviva Pharmaceuticals price target lowered to $3 from $7 at Roth Capital

Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on Reviva Pharmaceuticals (RVPH) to $3 from $7...

29d ago

RVPH

Reviva Pharmaceuticals price target lowered to $3 from $7 at Roth Capital

Roth Capital lowered the firm’s price target on Reviva Pharmaceuticals (RVPH) to $3 from $7 and keeps a...

29d ago

RVPH

Reviva Pharmaceuticals Advances Schizophrenia Treatment

Reviva Pharmaceuticals Holdings, Inc. ( ($RVPH) ) has released its Q2 earnings. Here is a breakdown of the...

28d ago

RVPH

Reviva Pharmaceuticals price target lowered to $2 from $5 at Maxim

Maxim analyst Jason McCarthy lowered the firm’s price target on Reviva Pharmaceuticals (RVPH) to $2 from $5 and...

1M ago

RVPH

Reviva Pharmaceuticals reports Q2 EPS (12c) vs. (26c) last year

As of June 30, the company’s cash and cash equivalents totaled approximately $10.4M. “The successful completion of our...

1M ago

RVPH

Reviva Pharmaceuticals Announces Public Offering Agreement

Reviva Pharmaceuticals Holdings ( ($RVPH) ) has shared an announcement. On June 26, 2025, Reviva Pharmaceuticals Holdings, Inc....

3M ago

RVPH

Reviva Pharmaceuticals prices 20M shares at 50c in public offering

Reviva Pharmaceuticals (RVPH) announced the pricing of its previously announced public offering with existing and new healthcare focused...

3M ago

RVPH

Reviva Pharmaceuticals announces common stock, warrants offering

Reviva Pharmaceuticals (RVPH) Holdings announced that it intends to offer shares of its common stock and warrants to...

3M ago

RVPH

Reviva Pharmaceuticals Holdings: Positive Phase 3 Data and Favorable Safety Profile Support Buy Rating

Reviva Pharmaceuticals Holdings (RVPH – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst...

3M ago

RVPH

Reviva Pharmaceuticals Completes Phase 3 Study for Schizophrenia

Reviva Pharmaceuticals Holdings ( ($RVPH) ) has issued an update. On June 2, 2025, Reviva Pharmaceuticals announced the...

4M ago

RVPH

Reviva Pharmaceuticals announces full dataset for one-year Phase 3 RECOVER study

Reviva Pharmaceuticals (RVPH) announced a full dataset and successful completion of the Company’s Phase 3 RECOVER open-label extension...

4M ago

RVPH

Reviva Pharmaceuticals Launches $50M At-Market Offering

Reviva Pharmaceuticals Holdings ( ($RVPH) ) has shared an announcement. On May 30, 2025, Reviva Pharmaceuticals Holdings, Inc....

4M ago

RVPH

RVPH FAQ

What was Reviva Pharmaceuticals Holdings’s price range in the past 12 months?

Reviva Pharmaceuticals Holdings lowest stock price was $0.30 and its highest was $4.28 in the past 12 months.

What is Reviva Pharmaceuticals Holdings’s market cap?

Reviva Pharmaceuticals Holdings’s market cap is $30.08M.

When is Reviva Pharmaceuticals Holdings’s upcoming earnings report date?

Reviva Pharmaceuticals Holdings’s upcoming earnings report date is Nov 17, 2025 which is in 62 days.

How were Reviva Pharmaceuticals Holdings’s earnings last quarter?

Reviva Pharmaceuticals Holdings released its earnings results on Aug 14, 2025. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of -$0.118 by -$0.002.

Is Reviva Pharmaceuticals Holdings overvalued?

According to Wall Street analysts Reviva Pharmaceuticals Holdings’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Reviva Pharmaceuticals Holdings pay dividends?

Reviva Pharmaceuticals Holdings does not currently pay dividends.

What is Reviva Pharmaceuticals Holdings’s EPS estimate?

Reviva Pharmaceuticals Holdings’s EPS estimate is -0.11.

How many shares outstanding does Reviva Pharmaceuticals Holdings have?

Reviva Pharmaceuticals Holdings has 68,003,620 shares outstanding.

What happened to Reviva Pharmaceuticals Holdings’s price movement after its last earnings report?

Reviva Pharmaceuticals Holdings reported an EPS of -$0.12 in its last earnings report, missing expectations of -$0.118. Following the earnings report the stock price went up 14.894%.

Which hedge fund is a major shareholder of Reviva Pharmaceuticals Holdings?

Currently, no hedge funds are holding shares in RVPH

Reviva Pharmaceuticals Holdings Stock Smart Score

Underperform

Fundamentals

Return on Equity

-916.17%

Trailing 12-Months

Asset Growth

44.48%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Reviva Pharmaceuticals Holdings

Reviva Pharmaceuticals Holdings (RVPH) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate, Brilaroxazine, is aimed at treating schizophrenia and other neuropsychiatric disorders. Reviva Pharmaceuticals operates primarily in the pharmaceutical sector, leveraging its proprietary technologies to advance its pipeline of drug candidates through clinical development.

Reviva Pharmaceuticals Holdings (RVPH) Earnings & Revenues

Historic Earnings Reports

RVPH Stock 12 Month Forecast

Average Price Target

$5.33

▲(1111.36% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"$12","-1":"-$1","2.25":"$2.25","5.5":"$5.5","8.75":"$8.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$11.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2.25,5.5,8.75,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Nov<br/>2024","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.44,1.2523076923076923,2.0646153846153847,2.876923076923077,3.6892307692307695,4.501538461538463,5.313846153846154,6.126153846153847,6.93846153846154,7.750769230769232,8.563076923076924,9.375384615384617,10.187692307692307,{"y":11,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.44,0.8161538461538461,1.1923076923076923,1.5684615384615384,1.9446153846153844,2.3207692307692307,2.6969230769230768,3.073076923076923,3.449230769230769,3.825384615384615,4.201538461538461,4.577692307692308,4.953846153846154,{"y":5.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.44,0.56,0.68,0.8,0.92,1.04,1.1600000000000001,1.28,1.4000000000000001,1.52,1.6400000000000001,1.76,1.8800000000000001,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.38,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.26,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.12,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.98,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.2,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.81,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.62,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.87,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.88,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >